INKT MiNK Therapeutics, Inc.

11d ago, source: Seeking Alpha

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT ...

This MiNK Therapeutics Insider Increased Their Holding In The Last Year

13d ago, source: Yahoo Finance

Viewing insider transactions for MiNK Therapeutics, Inc.'s (NASDAQ:INKT ) over the last year, we see that insiders were net ...

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

16d ago, source: Business Insider

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of ...

MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Call Transcript

1mon ago, source: Insider Monkey

Marc Van Dijk : Yeah. And also more broadly the autoimmune opportunity and we’ve been looking at this and Agenus is an antibody company, MiNK came out of an antibody company because there is an ...

Promising Clinical Progress and Market Potential for MiNK Therapeutics’ agenT-797 in Gastric Cancer Study

1mon ago, source: Business Insider

MiNK Therapeutics (INKT) Company Description: MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies ...

MiNK Therapeutics Inc INKT

7d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

MiNK Therapeutics Inc INKT

9d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

MiNK Therapeutics Inc.

28d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...